Boehringer Files Pradaxa Antidote, Could Lead To Reversible Novel Anticoagulant
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Finishing off a rolling BLA, company believes that the specific antidote for its novel anticoagulant Pradaxa will be eligible for accelerated approval based on Phase I data in volunteers.
You may also be interested in...
Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement
Settlement expected to resolve approximately 4,000 Pradaxa personal injury claims.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.